KERENDIA (Bayer Australia Ltd)
Product name
KERENDIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
181 (255 working days)
Active ingredients
finerenone
Registration type
NCE/NBE
Indication
KERENDIA (film-coated tablet) is indicated to delay progressive decline of kidney function in adults with chronic kidney disease associated with Type 2 diabetes (with albuminuria), in addition to standard of care (see section 5.1 Pharmacodynamic properties, Clinical trials).